Related Experiment Video
Updated: Mar 17, 2026
Isolation of Human Atrial Myocytes for Simultaneous Measurements of Ca2+ Transients and Membrane Currents
Published on: July 3, 2013
Pharmacokinetic Insights and Therapeutic Potential of Calcium Channel Blockers in Cardiovascular and
Krishana Kumar Sharma1, Mohit Panday1, Anamika Gautam1
1Department of Pharmacology, Teerthanker Mahaveer College of Pharmacy, Teerthanker Mahaveer University, Moradabad, Uttar Pradesh, 244001, India.
Insights
Calcium channel blockers (CCBs) are vital for managing cardiovascular diseases and show promise in cancer therapy. Research is exploring new CCBs and delivery methods to improve efficacy and reduce side effects.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Oncology
Background:
- Calcium channel blockers (CCBs) are essential for treating hypertension, angina, and arrhythmias.
- Cytochrome P450 metabolism significantly impacts CCB bioavailability and variability.
- Emerging research explores T-type CCBs for cancer treatment, utilizing nanocarriers to enhance drug delivery.
Purpose of the Study:
- To provide an updated overview of CCB pharmacokinetics, pharmacodynamics, and therapeutic uses.
- To review advancements in CCB development, including newer agents like cilnidipine and azelnidipine.
- To identify research gaps and future directions for optimizing CCB clinical utility.
Main Methods:
- Comprehensive literature review of pharmacokinetic and pharmacodynamic data.
- Analysis of therapeutic applications across cardiovascular, neurological, and oncological diseases.
- Evaluation of challenges in CCB treatment, including efficacy, side effects, and individualization.
Main Results:
- CCBs are crucial in managing various conditions, with expanding roles in neurology and oncology.
- First-pass metabolism by cytochrome P450 presents challenges in CCB dosing and bioavailability.
- Novel CCBs and nanocarrier systems offer potential solutions for improved therapeutic outcomes.
Conclusions:
- CCBs remain highly relevant in contemporary medicine, necessitating continued research.
- Optimizing CCB efficacy, minimizing side effects, and personalizing treatment are key future goals.
- Integrating current knowledge with emerging research will enhance the clinical application of CCBs.
Abstract:
Calcium channel blockers (CCBs) regulate calcium ion transport across cell membranes and are central to the management of hypertension, angina, arrhythmias, and cerebrovascular disorders, with emerging roles in neurological and oncological diseases. Most CCBs undergo significant first-pass metabolism mediated by cytochrome P450, which affects their interindividual variability, dosage, and bioavailability. Recent research highlights the potential of T-type CCBs in cancer treatment and the use of nanocarriers to overcome their low bioavailability and rapid metabolism. Since the introduction of verapamil in the 1960s, newer drugs with improved selectivity and safety, such as cilnidipine and azelnidipine, have been developed. Despite their widespread use, challenges remain in maximizing long-term efficacy, minimizing side effects, and individualizing treatment. This review provides an updated overview of the pharmacokinetics, pharmacodynamics, and therapeutic applications of dihydropyridine and non-dihydropyridine CCBs, while identifying research gaps and future directions to enhance their clinical utility. By integrating established pharmacological knowledge with recent advances, this study underscores the continued relevance of CCBs in modern medicine.
More Related Videos
07:42Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates
Published on: October 18, 2018
10:01High-Throughput Optical Controlling and Recording Calcium Signal in iPSC-Derived Cardiomyocytes for Toxicity Testing and Phenotypic Drug Screening
Published on: March 31, 2022
Related Concept Videos
01:18Antihypertensive Drugs: Action of Calcium Channel Blockers
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
01:17Antiepileptic Drugs: Calcium Channel Blockers
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers